Efficacy of Leishmania donovani ribosomal P1 gene as DNA vaccine in experimental visceral leishmaniasis

Experimental Parasitology

Volumn 129, Issue 1, 2011, Pages 55-64

  Masih, Shet ^a   Arora, Sunil K ^a   Vasishta, Rakesh K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Acidic ribosomal protein P1; DNA vaccine; Experimental leishmaniasis; Hamster model; Leishmania donovani

Indexed keywords

ACIDIC RIBOSOMAL PROTEIN P1; DNA VACCINE; FREUND ADJUVANT; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 4; LEISHMANIA VACCINE; PEPTIDE VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GENE; GENE EXPRESSION; GRANULOMA; HISTIOCYTE; HISTOPATHOLOGY; LEISHMANIA DONOVANI; LIVER; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MOLECULAR CLONING; MORTALITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PARASITE LOAD; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMASTIGOTE; RIBOSOMAL P1 GENE; SPLEEN; SYRIAN HAMSTER; TH1 CELL; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIGENS, PROTOZOAN; CLONING, MOLECULAR; CRICETINAE; CYTOKINES; GENE EXPRESSION; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIVER; LYMPHOCYTES; MESOCRICETUS; PHOSPHOPROTEINS; PROTOZOAN VACCINES; RANDOM ALLOCATION; RECOMBINANT PROTEINS; RIBOSOMAL PROTEINS; SPLEEN; VACCINES, DNA;

ANIMALIA; CRICETINAE; LEISHMANIA DONOVANI; PROTOZOA;

EID: 79960906779     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2011.05.014     Document Type: Article

References (41)

1. Arora S.K., Melby P.C., Sehgal S. Lack of serological specificity of recombinant heat shock protein of Leishmania donovani. Immunology and Cell Biology 1995, 73:446-451.
2. Arora S.K., Pal N.S., Mujtaba S. Leishmania donovani: identification of novel vaccine candidates using human reactive sera and cell lines. Experimental Parasitology 2005, 109:163-170.
3. Bhardwaj S., Vasishta R.K., Arora S.K. Vaccination with a novel recombinant Leishmania antigen along with MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis. Experimental Parasitology 2009, 121:29-37.
4. Bogdan C., Moll H., Solbach W., Rollinghoff M. Tumor necrosis factor-alpha in combination with interferon-gamma, but not with interleukin 4 activates murine macrophages for elimination of Leishmania major amastigotes. European Journal of Immunology 1990, 20:1131-1135.
5. Bradford M. A rapid and sensitive method for the Quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal of Biochemistry 1976, 72:248-254.
6. Bunn-Moreno M.M., Madeira E.D., Miller K., Menezes J.A., Campos-Neto A. Hypergammaglobulinaemia in Leishmania donovani infected hamsters: possible association with a polyclonal activator of B cells with suppression of T cell function. Clinical and Experimental Immunology 1985, 59:427-434.
7. Carvalho E.M., Badaro R., Reed S.G., Jones T.C., Johnson W.D. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. Journal of Clinical Investigations 1985, 76:2066-2069.
8. Coler R.N., Reed S.G. Second-generation vaccines against leishmaniasis. Trends in Parasitology 2005, 21:244-249.
9. De Luca P.M., Mayrink W., Alves C.R., Coutinho S.G., Oliveira M.P., Bertho A.L., et al. Evaluation of the stability and immunogenicity of autoclaved and non autoclaved preparations of a vaccine against American integumentary leishmaniasis. Vaccine 1999, 17:1179-1185.
10. Fujiwara R.T., Vale A.M., Franca da Silva J.C., da Costa R.T., QuetzJda S., Martins Filho O.A., et al. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Veterinary Research 2005, 36:827-838.
11. Ghose A.C., Haldar J.P., Pal S.C., Mishra B.P., Mishra K.K. Serological investigations on Indian kala-azar. Clinical and Experimantal Immunology 1980, 40:318-326.
12. Gifawesen C., Farrel J.P. Comparison of T-cell responses in self-limiting versus progressive visceral Leishmania donovani infections in golden hamsters. Infection and Immunity 1989, 57:3091-3096.
13. Gradoni L., Foglia Manzillo V., Pagano A., Piantedosi D., De Luna R., Gramiccia M., et al. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine 2005, 23:5245-5251.
14. Handman E. Leishmaniasis: Current Status of Vaccine Development. Clinical Microbiology Reviews 2001, 14:229-243.
15. Hernandez-Pando R., Bornstein Q.L., Aguilar Leon D., Orozco E.H., Madrigal V.K., Matrinez Cordero E. Inflammatory cytokine production by immunological and foreign body multinucleated giant cells. Immunology 2000, 100:352-358.
16. Herwaldt B.L. Leishmaniasis. Lancet 1999, 354:1191-1199.
17. Howard J.G. Immunological regulation and control of experimental leishmaniasis. International Reviews in Experimental Pathology 1986, 28:79-116.
18. Iborra S., Soto M., Carrion J., Nieto A., Fernandez E., Alonso C., et al. The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice. Infection and Immunity 2003, 71:6562-6572.
19. Kedzierski L., Zhu Y., Handman E. Leishmania vaccines: progress and problems. Parasitology 2006, 133:87-112.
20. Khalil E.A., El Hassan A.M., Zijlstra E.E., Mukhtar M.M., Ghalib H.W., Musa B.F., et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000, 356:1565-1569.
21. Levin M.J., Vazquez M., Kaplan D., Schijman A.G. The Trypanosomacruzi ribosomal P protein family: classification and antigenicity. Parasitology Today 1993, 9:381-384.
22. Mauel J., Behin R. Immunity: Clinical and experimental. The Leishmaniasis in Biology and Medicine 1987, vol. 2:731-739. Academic Press, London (U.K.).
23. Melby P.C., Tryon V.V., Chandrasekar B., Freeman G.L. Cloning of syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. Infection and Immunity 1998, 66:2135-2142.
24. Murray H.W. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrobial Agents and Chemotherapy 2001, 45:2185-2197.
25. Murray H.W. Granulomatous inflammation: host antimicrobial defense in the tissues in visceral leishmaniasis. Inflammation: Basic Principles and Clinical Correlates 1999, 977-994. Lippincott-Raven, Philadelphia (PA). J. Gallin (Ed.).
26. Pal N.S., Arora S.K. Recognition of Leishmania donovani by CD4+ T cells of naive healthy uninfected individuals. Journal of Parasitic Diseases 2003, 27:47-52.
27. Probst P., Skeiky Y.A., Steeves M., Gervassi A., Grabstein K.H., Reed S.G. A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-a production and expression of B7-1 in human Monocyte derived antigen presenting cells. European Journal of Immunology 1997, 27:2634-2642.
28. Reed S.G., Campos-Neto A. Vaccines for parasitic and bacterial diseases. Current Opinions in Immunology 2003, 15:456-460.
29. Requena J.M., Iborra S., Carrion J., Alonso C., Soto M. Recent advances in vaccines for leishmaniasis. Expert Opinion on Biological Therapy 2004, 4:1505-1517.
30. Rodrigues V., Silva J.S., Campos-Neto A. Selective inability of spleen antigen presenting cells from Leishmania donovani infected hamsters to mediate specific T cell proliferation to parasite antigens. Parasite Immunology 1992, 14:49-58.
31. Sacks D.L., Lal S.L., Shrivastava S.N., Black Well J., Neva F.A. An analysis of T cell responsiveness in Indian kala-azar. Journal of Immunology 1987, 138:908-913.
32. Sambrook J., Russel D.W. Molecular cloning-A laboratory Manual 2001, Cold Spring Harbor Laboratory Press, New York (NY). third ed.
33. Saunders B.M., Cooper A.M. Restraining mycobacteria- role of granulomas in mycobacterial infections. Immunology and Cell Biology 2000, 78:334-341.
34. Sharifi I., Fekri A.R., Aflatonian M.R., Khamesipour A., Nadim A., Mousri M.R., et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998, 351:1540-1543.
35. Skeiky Y.A.W., Benson D.R., Elwasila M., Badaro R., Burns J.M., Reed S.G. Antigens shared by Leishmania species and Trypanosoma cruzi: immunological comparison of the acidic ribosomal P0 proteins. Infection and Immunity 1994, 62:1643-1651.
36. Skeiky Y.A.W., Kennedy M., Kaufman D., Borges M.M., Guderian J.A., Scholler J.K., et al. LeIF: a recombinant Leishmania protein that induces an IL-12 mediated TH1 cytokine profile. Journal of Immunology 1998, 161:6171-6179.
37. Soto M., Requena J.M., Quijada L., Guzman F., Patarroyo M.E., Alonso C. Identification of the Leishmania infantumP0 ribosomal protein epitope in canine visceral leishmaniasis. Immunology Letters 1995, 48:23-28.
38. Stauber L.A., Franchino E.M., Grun J. An eight day method for screening compounds against Leishmania donovani in the golden hamster. Journal of Protozoology 1958, 5:269-273.
39. Stober C.B., Lange U.G., Roberts M.T., Alcami A., Blackwell J.M. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. Journal of Immunology 2005, 175:2517-2524.
40. Travi B.L., Osorio Y., Melby P.C., Chandrasekar B., Arteaga L., Saravia N.G. Gender is a major determinant of the clinical evolution and immune response in hamsters infected with Leishmania spp. Infection and Immunity 2002, 70:2288-2296.
41. Vasconcellos RCS, Urago KP, Bunn-Moreno MM Madeira ED., 1996. Suppressor activity in Leishmania donovani-infected hamster serum: reversion by delipidated bovine serum albumin and role in cell cycle events. Brazilian Journal of Medical and Biological Research 29: 615-622. WHO Technical Report Series, 2000.